Lipigon Pharmaceuticals AB(LPGO)

Description: Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases. The company was incorporated in 2010 and is based in Umeå, Sweden.

---

Keywords: Organ Systems Rare Diseases Gene Therapy Cardiovascular Disease Metabolic Disease Lipid Metabolic Disorders Acute Respiratory Distress Syndrome Dyslipidemia Hyperlipidemia Respiratory Distress Syndrome Hypertriglyceridemia Lipodystrophy Familial Chylomicronemia Syndrome Lipoprotein Lipase Deficiency Lipid Metabolism Disorders

---

Home Page: www.lipigon.se

TvistevAegen 48 C
Umeå, 90736
Sweden
Phone: 46 7 05 78 17 68

---

Officers

Exchange: ST

Country: SE

Currency: Swedish krone (kr)